WEBULL
WebtradeDownload

Ascendis Pharma (ASND) Following Fresh TransCon Data Looks Undervalued To Bulls

Simply Wall St · 2d ago

Ascendis Pharma (NasdaqGS:ASND) is back in focus after new trial data on TransCon PTH showed sustained kidney function gains in adults with hypoparathyroidism over periods of up to five years.

Recent trading in Ascendis Pharma reflects cautious optimism. The latest move to a US$245.15 share price follows a 7 day share price return of 6.6% and a 30 day share price return of 8.7%, even though the 90 day share price return is down 3.7%. This suggests that momentum has started to improve again as fresh TransCon data and regulatory progress on YUVIWEL gain attention.

Capitalize on Ascendis Pharma’s momentum around TransCon therapies by scanning a curated 34 healthcare AI stocks that could be lining up their own next clinical or regulatory catalysts.

Bulls point to Ascendis Pharma’s TransCon traction and rich rare disease portfolio. Bears see a US$245.15 price already baking in a lot of hope. Which side does the current valuation actually lean toward?

Most Popular Narrative: 20.7% Undervalued

Ascendis Pharma’s most followed narrative pegs fair value at about $309 per share, compared with the recent $245.15 close. This frames the current TransCon excitement as only part of a larger long term thesis anchored in platform economics and royalty clarity.

Partnerships such as the collaboration with Novo Nordisk on once monthly TransCon semaglutide and ex U.S. partners like Teijin for endocrine products extend the TransCon model into larger disease areas and additional geographies. This can add new royalty or collaboration streams alongside product sales and support earnings as R&D productivity improves.

See why 5 investors see Ascendis Pharma as 21% undervalued.

Result: Fair Value of $309 (UNDERVALUED)

Still, the bullish Ascendis Pharma story runs into trouble if Yorvipath uptake plateaus or if Yuviwel royalties and launch costs squeeze the long term margin profile.

Find out about the key risks to this Ascendis Pharma narrative.

Another View: What Ascendis Pharma’s P/E Is Telling You

There is a different story in the P/E math. Ascendis Pharma trades at 19.4x earnings, slightly above the US Biotechs average of 18.6x but well below a 28x peer average and a 22.4x fair ratio. That mix points to both upside potential and mispricing risk. Which side do you think wins out?

See what the numbers say about this price in our valuation breakdown, then weigh it against your own expectations for TransCon execution and cash generation over the next few years. See what the numbers say about this price — find out in our valuation breakdown.

For a visual read on how Ascendis Pharma’s current earnings multiple compares with the wider sector, start with this simple comparison chart:

NasdaqGS:ASND P/E Ratio as at Oct 2026
NasdaqGS:ASND P/E Ratio as at Oct 2026

Next Steps

Mixed signals around Ascendis Pharma’s valuation and clinical progress leave plenty of room for debate, so review the full picture and pressure test your own thesis with the 4 key rewards and 1 important warning sign.

Looking for more Ascendis Pharma style investment ideas?

If Ascendis Pharma has sharpened your focus on quality opportunities, keep that momentum going with targeted screens that surface stocks matching specific traits you care about.